Letter: Third-line therapy in acute severe ulcerative colitis, exploring the uncertainty and unanswered questions-Authors' reply
- PMID: 38845358
- DOI: 10.1111/apt.18104
Letter: Third-line therapy in acute severe ulcerative colitis, exploring the uncertainty and unanswered questions-Authors' reply
Comment on
-
Letter: Third-line therapy in acute severe ulcerative colitis, exploring the uncertainty and unanswered questions.Aliment Pharmacol Ther. 2024 Jul;60(2):298-299. doi: 10.1111/apt.18056. Epub 2024 Jun 3. Aliment Pharmacol Ther. 2024. PMID: 38828835 No abstract available.
References
REFERENCES
-
- Chetwood JD, Ding NS. Letter: third‐line therapy in acute severe ulcerative colitis, exploring the uncertainty and unanswered questions. Aliment Pharmacol Ther. 2024;60:298–299.
-
- García MJ, Riestra S, Amiot A, Julsgaard M, García de la Filia I, Calafat M, et al. Effectiveness and safety of a third‐line rescue treatment for acute severe ulcerative colitis refractory to infliximab or ciclosporin (REASUC study). Aliment Pharmacol Ther. 2024;59:1248–1259. https://doi.org/10.1111/apt.17938
-
- Kayal M, Posner H, Milwidsky HM, Plietz M, Khaitov S, Sylla P, et al. Acute severe ulcerative colitis is associated with an increased risk of acute Pouchitis. Inflamm Bowel Dis. 2023;29(12):1907–1911.
-
- Spinelli A, Bonovas S, Burisch J, Kucharzik T, Adamina M, Annese V, et al. ECCO guidelines on therapeutics in ulcerative colitis: surgical treatment. J Crohn's Colitis. 2022;16(2):179–189.
-
- Rivière P, Suen CLW, Chaparro M, De Cruz P, Spinelli A, Laharie D. Acute severe ulcerative colitis management: unanswered questions and latest insights. Lancet Gastroenterol Hepatol. 2024;9(3):251–262.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical